SCHEMBL5122891

SCHEMBL5122891

C1CCC(NC2CCCCC2)CC1.C[C@@H](C(=O)O)N(C(=O)OCc1ccccc1)C1CCCCC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
ENPP2 Q13822 1/20 0.47
EPHX1 P07099 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
SIGMAR1 Q99720 1/20 0.44
GAA P10253 2/20 0.42
SGMS2 Q8NHU3 1/20 0.41
EPHX2 P34913 1/20 0.41
CCR5 P51681 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
SCN1A P35498 1/20 0.40
SCN2A Q99250 1/20 0.40
SCN3A Q9NY46 1/20 0.40
TSHR P16473 1/20 0.40
CTSK P43235 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27652104 1.00 ALDH1A1 (0.52) ALDH1A1ENPP2EPHX1MEN1KMT2A
SCHEMBL5123960 1.00 ALDH1A1 (0.52) ALDH1A1ENPP2EPHX1MEN1KMT2A
SCHEMBL1799143 0.93 ENPP2 (0.52) ALDH1A1ENPP2EPHX1MEN1KMT2A
SCHEMBL5981283 0.93 ENPP2 (0.52) ALDH1A1ENPP2EPHX1MEN1KMT2A
SCHEMBL7033170 0.93 ENPP2 (0.52) ALDH1A1ENPP2EPHX1MEN1KMT2A
SCHEMBL7275332 0.87 ENPP2 (0.49) ALDH1A1ENPP2EPHX1MEN1KMT2A
SCHEMBL7382258 0.87 ALDH1A1 (0.46) ALDH1A1ENPP2KMT2ASIGMAR1GAA
SCHEMBL27556768 0.82 ENPP2 (0.45) ENPP2SIGMAR1CTSK
SCHEMBL4420999 0.82 ENPP2 (0.45) ENPP2SIGMAR1CTSK
SCHEMBL7375518 0.81 SIGMAR1 (0.44) ALDH1A1ENPP2MEN1KMT2ASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021025-A1 INHIBITORS OF CATHEPSIN S LIU HONG 2008-01-24 US disclosed
US-7297714-B2 Selective in presence of at least one other cathepsin isozyme; such as (3-cyclopentyl-{[5-(3-fluoro-phenyl)-furan-2-carbonyl]-amino}-propionylamino)-4-oxo-butyric acid IRM LLC (BM) 2007-11-20 US disclosed
EP-1677782-A2 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2006-07-12 EP disclosed
US-20050130959-A1 Inhibitors of cathepsin S IRM LLC (BM) 2005-06-16 US disclosed
WO-2005039496-A2 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021025-A1 INHIBITORS OF CATHEPSIN S CTSS, CTSB, CTSZ ALDH1A1 3512/4885ENPP2 172/4885EPHX1 2325/4885
US-20050130959-A1 Inhibitors of cathepsin S CTSS, CTSB, CTSZ ALDH1A1 3512/4885ENPP2 172/4885EPHX1 2325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.